1-异丁基-2-碘-苯 | 855274-94-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-异丁基-2-碘-苯
• 英文名称: 1-isobutyl-2-iodo-benzene
• 英文别名: 1-Isobutyl-2-jod-benzol；isobutyl-phenyliodide；1-Iodo-2-(2-methylpropyl)benzene
• CAS: 855274-94-1
• 化学式: C₁₀H₁₃I
• 分子量: 260.118
• InChiKey: FMRLYKFBDKTYFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-异丁基-2-碘-苯 在 magnesium 作用下， 生成 苯甲酸,2-(2-甲基丙基)-
  参考文献：
  名称：

  镁和格氏试剂对某些苄基醚的作用。第二部分 格利雅的作用试剂上ø - ，米- ，和p甲氧基-苯氧基和- methylanilines

  摘要：

  DOI：

  10.1039/jr9540004127
• 作为产物：
  描述：

  2-(甲氧基甲基)苯胺 在 乙醚 、 硫酸 、 sodium nitrite 作用下， 生成 1-异丁基-2-碘-苯
  参考文献：
  名称：

  镁和格氏试剂对某些苄基醚的作用。第二部分 格利雅的作用试剂上ø - ，米- ，和p甲氧基-苯氧基和- methylanilines

  摘要：

  DOI：

  10.1039/jr9540004127

文献信息

• Two-photon absorbing compounds and methods of making same
  申请人：The United States of America, as represented by the Secretary of the Air Force

  公开号：US10113065B1

  公开（公告）日：2018-10-30

  A two-photon absorbing (TPA) compound is provided, along with a method of making same. The TPA compound has a general structural formula: where A is an acceptor moiety that is connected to m number of diarylaminofluorene arms (m=1-3); in each diarylaminofluorene arms, R is selected from linear or branched alkyl chains having a general formula CnH2n+1, where n is in a range from 2 to 25; where R1, R2, and R3 are independently selected from H or C1-C4 alkyls; where R4 is selected from C1-C5 alkyls; and wherein R5 through R10 are independently selected from H, alkoxyls, alkyls, or aryls. A may be benzothiazol-2-yl, benzo[1,2-d:4,5-d′]bisthiazole-2,6-diyl, thiazolo[5,4-d]thiazole-2,5-diyl-, 1,3,5-triazine-2,4,6-triyl, 1,3,5-triazine-2,4,6-triyl, benzo[1,2-d:3,4-d′:5,6-d″]tristhiazole-2,5,8-triyl-, or dithieno[3,2-b:2′,3′-d]thiophene-2,6-diyl-.

  提供了一种双光子吸收（TPA）化合物，以及制造该化合物的方法。TPA化合物具有一般的结构公式：其中A是一个受体基团，它与m个二芳基氨基荧烷臂（m = 1-3）相连；在每个二芳基氨基荧烷臂中，R选自具有一般公式CnH2n+1的直链或支链烷基链，其中n的范围从2到25；其中R1、R2和R3独立地选自H或C1-C4烷基；其中R4选自C1-C5烷基；R5至R10独立地选自H、烷氧基、烷基或芳基。A可以是苯并噻唑-2-基，苯并[1,2-d:4,5-d']二噻唑-2,6-二基，噻唑[5,4-d]噻唑-2,5-二基，1,3,5-三嗪-2,4,6-三基，1,3,5-三嗪-2,4,6-三基，苯并[1,2-d:3,4-d':5,6-d"]三噻唑-2,5,8-三基，或二噻吩[3,2-b:2',3'-d]噻吩-2,6-二基。
• Iron-Catalyzed Remote Arylation of Aliphatic C–H Bond via 1,5-Hydrogen Shift
  作者：Bingwei Zhou、Hiroki Sato、Laurean Ilies、Eiichi Nakamura

  DOI：10.1021/acscatal.7b03458

  日期：2018.1.5

  arylation of 2-iodoalkylarenes with diphenylzinc selectively at the γ C–H bond of the alkyl side chain. Several lines of evidence suggest that the iron catalyst reacts with the aryl iodide moiety of the substrate to generate an aryliron intermediate that behaves in a radical manner and cleaves the aliphatic C–H bond through 1,5-hydrogen transfer; the resulting alkyliron intermediate undergoes reductive elimination

  催化量的铁（III）盐和N-杂环卡宾配体催化2-碘烷基芳烃与二苯基锌在烷基侧链的γC–H键上选择性地芳基化。有几条证据表明，铁催化剂与底物的芳基碘化物反应生成芳基铁中间体，该中间体以自由基的方式起作用，并通过1，5-氢转移裂解脂肪族CH键。所得的烷基铁中间体经过还原消除，得到芳基化产物。
• [EN] 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS MARQUÉS AU 18/19F QUI CIBLENT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
  申请人：BRITISH COLUMBIA CANCER AGENCY BRANCH

  公开号：WO2017117687A1

  公开（公告）日：2017-07-13

  This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each Rl is an anionic group, L is a linker and R2BF3 is - N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.

  这项披露涉及包含带有带正负电荷的三氟硼酸酯假体基团的新型化合物，其靶向前列腺特异性膜抗原（PSMA），例如在前列腺癌中。这些化合物具有式I，其中每个Rl是一个阴离子基团，L是一个连接基团，R2BF3是-N（R3）2CH2BF3，一个取代有BF3或甲基BF3的吡啶基团，或取代有甲基BF3的唑基团。还披露了用于成像和治疗表达PSMA的癌症的方法和用途。
• Purine compounds and methods of use thereof
  申请人：Salzman L. Andrew

  公开号：US20070238694A1

  公开（公告）日：2007-10-11

  The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, diabetes, a cellular proliferative disorder, a skin disorder, a radiation-induced injury, a wound or an inflammatory disease comprising administering an effective amount of a Purine Compound to a subject in need thereof.

  这项发明涉及嘌呤化合物；包含有效量嘌呤化合物的组合物；以及用于减少受试者代谢率或在心脏停搏期间保护受试者心脏免受心肌损伤，或用于治疗或预防心血管疾病、神经系统紊乱、缺血情况、再灌注损伤、肥胖、消耗性疾病、糖尿病、细胞增殖紊乱、皮肤疾病、辐射诱导损伤、创伤或炎症疾病的方法，包括向需要的受试者施用有效量的嘌呤化合物。
• N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150284389A1

  公开（公告）日：2015-10-08

  Disclosed are compounds of Formula A A and Formula A B : wherein “Heteroaryl-1”, R A1 , R A2 , R B1 , and R C are defined herein, which novel compounds have properties for blocking Na 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formulae A A and A B or their salts, and methods of treating neuropathic pain disorders using the same.

  本发明涉及式AA和式AB的化合物：其中“Heteroaryl-1”，RA1，RA2，RB1和RC在此定义，这些新型化合物具有阻断周围和交感神经元中发现的Na 1.7离子通道的特性。还描述了包含式AA和AB或其盐的制药配方，以及使用它们治疗神经病理性疼痛障碍的方法。